<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;SERPINA1&lt;/i&gt; (alpha-1 antitrypsin gene)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>SERPINA1</i> (alpha-1 antitrypsin gene)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>SERPINA1</i> (alpha-1 antitrypsin gene)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James K Stoller, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1025596101"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph discusses the interpretation and possible interventions following genetic testing of the <em>SERPINA1</em> gene, which encodes alpha-1 antitrypsin (AAT). It is not intended to replace clinical judgment in the decision to test or the care of the individual who was tested. </p><p>AAT deficiency (AATD) predisposes to obstructive lung disease and sometimes liver disease and other complications. Indications for testing and management of disease complications are discussed separately in UpToDate [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4086935069"><span class="h1">HOW TO READ THE REPORT</span><span class="headingEndMark"> — </span>The table summarizes important considerations when reviewing the report  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>); these include obtaining a hard copy, confirming patient identity, determining whether the result is current, and reviewing which variant(s) were tested.</p><p>Another table provides a glossary of terms  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>).</p><p>Most but not all individuals with alpha-1 antitrypsin deficiency (AATD) will be identified with genetic tests that probe for common disease alleles using single nucleotide polymorphism (SNP) probes (see <a class="local">'SERPINA1 genetics'</a> below). For results (positive or negative) that would impact clinical care, a clinician must review the report to ascertain how the genotype was determined, which alleles were assessed, and whether additional testing is needed.</p><p class="headingAnchor" id="H532533867"><span class="h1"><i>SERPINA1</i> GENETICS</span></p><p class="headingAnchor" id="H3290846663"><span class="h2">Overview of variants</span><span class="headingEndMark"> — </span><em>SERPINA1</em> encodes alpha-1 antitrypsin (AAT), a protease inhibitor that inhibits neutrophil elastase and other proteases. Excess or uncontrolled neutrophil elastase activity breaks down lung tissue.</p><p>Over 150 <em>SERPINA1</em> variants have been identified. Most are point mutations that introduce a single amino acid substitution and reduce AAT level and/or function. Many laboratories test for common variants using selected single nucleotide polymorphism (SNP) probes rather than gene sequencing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variant nomenclature</strong> – Variants are often named with PI (for protease inhibitor) followed by a letter that reflects the migration of the associated protein on an isoelectric focusing (IEF) gel [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"M" (Middle of the gel) designates the protein from the normal allele. Variants within M (M1-M4) have no clinical significance. Rare pathogenic variants produce proteins that migrate in the M region of the gel (eg, M<sub>Malton</sub>, M<sub>Heerlen</sub>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Letters of the alphabet before M (A, F, I) designate variants that produce faster migrating proteins; letters after M (S, Z) designate variants that produce slower migrating proteins. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>"Z" is the most common disease allele. Z produces an AAT level approximately 10 to 20 percent of normal. Homozygosity for Z (written as PI ZZ, Pi ZZ, or PI*ZZ) causes marked AAT deficiency (AATD). Z also confers impaired AAT function, which further increases emphysema risk. In addition, the protein encoded by the Z allele forms abnormal polymers within hepatocytes, which can cause liver disease, sometimes severe. Polymers produced by alveolar macrophages may also contribute to lung disease, as polymers are chemotactic for neutrophils, thereby potentially increasing the neutrophil elastase burden in the lung. (See <a class="local">'Genotype-phenotype correlations'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>"S" and "I" are less common alleles that cause mild deficiency (AAT serum levels approximately 60 to 80 percent of normal).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>"F" confers normal AAT levels but impaired function in binding neutrophil elastase.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other alleles are summarized in the table  (<a class="graphic graphic_table graphicRef103267" href="/z/d/graphic/103267.html" rel="external">table 3</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific variant names</strong> – A specific variant may be reported using the amino acid substitution it confers. As an example, the Z allele may be called Glu342Lys (lysine substituted for the normal glutamic acid at position 342). </p><p></p><p class="bulletIndent1">The position of the base-pair substitution can also be indicated (for Z: c.1096G&gt;A), or the reference SNP cluster identification (rs ID) tag can be used (for Z: rs28929474). These designations are less commonly used clinically but may appear in genetic test reports.</p><p></p><p>Some genetic tests are performed concomitantly with serum AAT assays, usually measured by nephelometry and reported in mg/dL; this result can be converted to micromoles by dividing mg/dL by 5.20.</p><p>If an individual is tested using SNP probes and they have a disease variant not covered by the probes, the report will indicate "no abnormal allele found." If the serum AAT level is low, further diagnostic testing is needed, often with exome or whole gene sequencing. </p><p class="headingAnchor" id="H3469990070"><span class="h2">Genotype-phenotype correlations</span><span class="headingEndMark"> — </span>Correlation (or lack thereof) between <em>SERPINA1</em> genotype and clinical phenotype (serum AAT level or clinical status) can be highly informative:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correlation with AAT level</strong> – Serum AAT levels usually correlate with genotype. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal range </strong>– The AAT normal range is approximately 100 to 220 mg/dL (20 to 53 micromol/L); the lower limit of normal is approximately 100 mg/dL (20 micromol/L) [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe deficiency</strong> – An individual's AAT level is determined by the pair of alleles that confers their genotype  (<a class="graphic graphic_table graphicRef129289" href="/z/d/graphic/129289.html" rel="external">table 4</a>).<em> </em>Homozygosity for an allele associated with severe deficiency, such as PI*ZZ, will generally produce a serum AAT level in the range of 15 to 20 mg/dL (3 to 7 micromol/L). True null alleles (AAT level 0 mg/dL) are very rare. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Effect of inflammation and pregnancy</strong> – AAT is an acute phase reactant; levels can increase with inflammation, especially in PI*MM individuals (unaffected) or PI*MZ heterozygotes. In PI*ZZ individuals, the magnitude of rise in the serum AAT level during inflammation is low. Levels also increase (by up to threefold) during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/417.html" rel="external">"Normal reference ranges for laboratory values in pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Qualitative defect</strong> – The rare F allele (Arg223Cys) produces a purely qualitative defect (normal AAT levels, abnormal function). F homozygotes (PI*FF) have an increased emphysema risk.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Need for additional genetic testing</strong> – Severe AATD for which genetic testing does not identify a deficiency allele suggests an atypical variant or missed identification of a variant; a gene panel, exome sequencing, or whole gene sequencing is almost always indicated. Specialist involvement is advised to ensure this is done correctly. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correlation with clinical findings</strong> – The most common disease variant (Z) predisposes to both lung and liver disease (see <a class="local">'Overview of variants'</a> above). The mechanisms of lung and liver disease differ:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lung disease</strong> – The risk for emphysema generally correlates with the serum AAT level. An AAT level of ≥57 mg/dL (≥11 micromol/L) is considered a protective threshold above which emphysema risk is generally not increased; below this level, risk is elevated. All PI*ZZ homozygotes have levels well below 57 mg/dL. PI*ZZ homozygotes also have a qualitative defect (dysfunctional AAT protein with reduced neutrophil elastase binding).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver disease </strong>– Some variants produce protein that polymerizes abnormally in hepatocytes  (<a class="graphic graphic_table graphicRef103267" href="/z/d/graphic/103267.html" rel="external">table 3</a>). Examples include Z, S<sub>Iiyama</sub>, King's, and M<sub>Malton</sub>. Accumulation of polymerized AAT can cause chronic liver fibrosis starting in childhood that can progress to cirrhosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Increased risk for venous thromboembolism (VTE). (See  <a class="medical medical_review" href="/z/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Vascular disease'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Increased risk for inflammatory bowel disease. (See  <a class="medical medical_review" href="/z/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Inflammatory bowel disease'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Increased risk for cancer, especially liver cancer. (See  <a class="medical medical_review" href="/z/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Hepatic disease'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Homozygosity for Z can also cause panniculitis and antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis. (See  <a class="medical medical_review" href="/z/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The rare Pittsburgh variant (Met358Arg) can cause a bleeding tendency. </p><p></p><p class="headingAnchor" id="H1799483732"><span class="h1">CLINICAL IMPLICATIONS</span><span class="headingEndMark"> — </span>Alpha-1 antitrypsin deficiency (AATD) is an autosomal recessive disorder  (<a class="graphic graphic_figure graphicRef50124" href="/z/d/graphic/50124.html" rel="external">figure 1</a>), although the effects on alpha-1 antitrypsin (AAT) level are autosomal codominant (each allele contributes 50 percent to the serum AAT level). AATD is most common in individuals of European ancestry and is significantly underdiagnosed  (<a class="graphic graphic_table graphicRef129289" href="/z/d/graphic/129289.html" rel="external">table 4</a>).</p><p>Clinical implications of genetic test results depend on the genotype, as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef129469" href="/z/d/graphic/129469.html" rel="external">algorithm 1</a>) and discussed below. (See <a class="local">'Heterozygotes'</a> below and <a class="local">'Homozygotes/compound heterozygotes'</a> below and <a class="local">'Negative test'</a> below.)</p><p class="headingAnchor" id="H2442026529"><span class="h2">Positive test</span></p><p class="headingAnchor" id="H760421395"><span class="h3">Heterozygotes</span><span class="headingEndMark"> — </span>Heterozygotes for a <em>SERPINA1</em> severe deficiency variant (eg, PI*MZ or PI*SZ) may be unaffected carriers and generally are not at increased risk of emphysema if they do not smoke and lack other inhalation exposures (industrial dust, biomass fuel exposure). They have intermediate AAT levels. Heterozygotes with a Z allele (eg, PI*MZ, PI*SZ) who smoke have an increased risk for emphysema, and PI*MZ heterozygotes may develop liver disease, especially with another hepatic insult (eg, steatohepatitis). </p><p>If confidence is high that an individual is heterozygous, serum AAT testing typically is not needed; however, it may be obtained by some clinicians. Nonsmoking heterozygotes with an AAT level ≥57 mg/dL (≥11 micromol/L) generally do not require further testing. Heterozygotes who smoke should be strongly advised to stop smoking. They are also counseled to avoid passive smoke and to inform their first-degree relatives to allow further counseling and testing.</p><p>The table summarizes additional aspects of management  (<a class="graphic graphic_table graphicRef129289" href="/z/d/graphic/129289.html" rel="external">table 4</a>). </p><p class="headingAnchor" id="H1895855846"><span class="h3">Homozygotes/compound heterozygotes</span><span class="headingEndMark"> — </span>Homozygotes or compound heterozygotes for pathogenic variants have an increased risk for disease, although some may be unaffected due to variable penetrance and variable expressivity. </p><p>Surveillance for complications and decisions regarding timing of interventions is best managed by a disease expert. The following may be indicated  (<a class="graphic graphic_table graphicRef129289" href="/z/d/graphic/129289.html" rel="external">table 4</a>) [<a href="#rid4">4-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Baseline pulmonary function tests (PFTs, including spirometry [with postbronchodilator testing if prebronchodilator tests show airflow obstruction] and diffusing capacity) and chest computed tomography (CT).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Avoid smoking and other respiratory exposures. Evidence is lacking regarding the risks of vaping, marijuana use, and industrial/occupational exposures, but avoidance appears prudent, especially for inhaled substances that may cause inflammation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> – The following may be appropriate, with shared decision-making [<a href="#rid4">4</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>PFTs annually or twice yearly</p><p class="bulletIndent3"><span class="glyph">-</span>Intravenous enzyme replacement (augmentation therapy)</p><p class="bulletIndent3"><span class="glyph">-</span>Consider lung transplant for severe disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Baseline examination for liver disease, liver ultrasound, elastography, liver biochemical tests, and complete blood count (CBC) to assess platelet count</p><p class="bulletIndent3"><span class="glyph">-</span>Vaccination against hepatitis A and B viruses</p><p class="bulletIndent3"><span class="glyph">-</span>Avoid alcohol, excess body weight, other sources of liver injury </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Standard cirrhosis therapy</p><p class="bulletIndent3"><span class="glyph">-</span>Consider liver transplant for severe disease by Model for End-stage Liver Disease (MELD) criteria </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other risks</strong> – Heightened level of suspicion and low threshold for evaluating other complications including VTE, inflammatory bowel disease, and cancer (especially liver cancer)</p><p></p><p class="headingAnchor" id="H3155087293"><span class="h2">Negative test</span><span class="headingEndMark"> — </span>A negative test may be sufficient to exclude disease risk, with important exceptions:</p><p class="bulletIndent1"><span class="glyph">●</span>If genetic testing is negative but the AAT level is low, referral to a genetics expert or disease specialist is needed to explain the discordance and determine next steps.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If testing is negative (normal AAT level and/or no variants on genetic testing) but clinical features suggest AATD (emphysema in a nonsmoker or liver disease that remains unexplained after an evaluation), specialist evaluation may be indicated to identify new or rare causative variants in <em>SERPINA1</em> or other causes of the findings.</p><p></p><p class="headingAnchor" id="H2589644371"><span class="h1">RELATIVES</span><span class="headingEndMark"> — </span>The range of serum alpha-1 antitrypsin (AAT) levels in heterozygotes can be quite broad; genotyping is considered more helpful than AAT level in individuals with a known familial disease variant. This is appropriate at any age because children are at risk for liver disease, and avoidance of second-hand smoke is prudent. </p><p class="bulletIndent1"><span class="glyph">●</span>First-degree relatives (siblings, parents, and children) of all PI*ZZ individuals should be genotyped. Potential genotypes in offspring depend on the genotypes of their parents: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both parents are Z homozygotes (PI*ZZ) – All children will be homozygous.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both parents are Z heterozygotes (PI*MZ) – Children have a 25 percent chance of being homozygous, 50 percent chance of being heterozygous, and 25 percent chance of being unaffected noncarriers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One parent is a Z homozygote and one is a Z heterozygote (PI*ZZ and PI*MZ) – Children have a 50 percent chance of being homozygous and 50 percent chance of being heterozygous.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First-degree relatives of individuals with other <em>SERPINA1</em> genotypes (Z heterozygotes, compound heterozygotes, homozygotes for other disease alleles) may also be offered testing and counseling. The strength of recommendation for testing is summarized in a joint guideline from the American Thoracic Society (ATS) and European Respiratory Society (ERS) [<a href="#rid5">5,6</a>]. Consultation with a disease specialist or genetics expert may be helpful. (See <a class="local">'Resources'</a> below.)</p><p></p><p class="headingAnchor" id="H64847527"><span class="h1">RESOURCES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specialists</strong> – Clinical assessment can be done by an appropriate specialist (pulmonologist or hepatologist/gastroenterologist). Those who require further counseling and/or testing of relatives may benefit from individual or family consultation with a genetics professional.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AATD specialists – Alpha-1 Foundation (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Falpha1.org%2Ffind-an-alpha-1-specialist%2F&amp;token=PYblK7KiKBuiT1M28CFhCnu3gXxzHjQ%2FqizTgphU7QbZk5b%2BpwmPhGfZktieILgnMLNBVP7DpBeRE3gIB9S9Tg%3D%3D&amp;TOPIC_ID=129159" target="_blank">alpha1.org</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=129159" target="_blank">ACMG</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=129159" target="_blank">NSGC</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UpToDate topics on AATD</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary – (See  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Extrapulmonary – (See  <a class="medical medical_review" href="/z/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment – (See  <a class="medical medical_review" href="/z/d/html/1434.html" rel="external">"Treatment of alpha-1 antitrypsin deficiency"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Crowther DC, Belorgey D, Miranda E, et al. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. Eur J Hum Genet 2004; 12:167.</a></li><li><a class="nounderline abstract_t">Brantly ML, Wittes JT, Vogelmeier CF, et al. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 1991; 100:703.</a></li><li><a class="nounderline abstract_t">Sandhaus RA, Turino G, Brantly ML, et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis 2016; 3:668.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.</a></li><li><a class="nounderline abstract_t">Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J 2017; 50.</a></li></ol></div><div id="topicVersionRevision">Topic 129159 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694355" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889260" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28848891" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522813" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29191952" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : European Respiratory Society statement: diagnosis and treatment of pulmonary disease inα1-antitrypsin deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
